Retinoids synergize with interleukin-2 to augment IFN-γ and interleukin-12 production by human peripheral blood mononuclear cells

被引:35
作者
Fox, FE
Kubin, M
Cassin, M
Niu, Z
Trinchieri, G
Cooper, KD
Rook, AH
机构
[1] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA
[2] Wistar Inst, Philadelphia, PA 19104 USA
[3] Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA
关键词
D O I
10.1089/107999099314117
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have demonstrated previously that cells from both the skin and peripheral blood from patients with cutaneous T cell lymphoma (CTCL) have elevated levels of protein and mRNA for Th2 cytokines, interleukin-4 (IL-4) and IL-5, and depressed levels of Th1 cytokines, IL-2 and interferon-gamma (IFN-gamma), Furthermore, IL-12 in vitro can restore IFN-gamma production by these patients' cells tot near normal levels, Because retinoids exert therapeutic activity in CTCL and are potent modulators of growth and differentiation of hematopoietic cells, we investigated the role of retinoids in modulating Th1 cytokine production. Peripheral blood mononuclear cells (PBMC) from normal donors and patients with CTCL were cultured with medium, IL-2, 13-cis-retinoic acid, all-trans-retinoic acid, acetretin or etretinate alone, or IL-2 plus the retinoids for 24 h, and levels of IFN-gamma. were determined using ELISA, IL-2 or retinoids alone could induce low but significant levels of IFN-gamma, However, when IL-2 was cultured with each retinoid, a synergistic augmentation of IFN-gamma levels (4-fold to 90-fold) was observed except in the case of etretinate, All-trans-retinoic acid (ATRA) was the most potent IFN-gamma inducer. Similar studies performed using PBMC from CTCL patients indicated the IFN-gamma augmentation occurred but in a blunted manner. The IFN-gamma-inducing effect of ATRA and 13-cis-retinoic acid could be abrogated by addition of anti-IL-12 antibodies, suggesting that IL-12 plays a role in the synergistic upregulation of IFN-gamma, Using an IL-12 p40-specific radioimmunoassay (RIA), we confirmed the presence of IL-12 in IL-2 plus retinoid-treated culture supernatants. Purified monocytes cultured with IL-2 plus ATRA did not secrete IL-12. Only when monocytes were cocultured with lymphocytes was there an increase in IL-12 production, suggesting the involvement of a paracrine feedback loop requiring both monocytes and lymphocytes. These data suggest that retinoids can induce Th1 cytokines from normal and CTCL PBMC and that this induction may be mediated through IL-12 production.
引用
收藏
页码:407 / 415
页数:9
相关论文
共 28 条
[1]  
BERGER C, 1994, J INVEST DERMATOL, V102, P566
[2]   TRANSPORT AND STORAGE OF VITAMIN-A [J].
BLOMHOFF, R ;
GREEN, MH ;
BERG, T ;
NORUM, KR .
SCIENCE, 1990, 250 (4979) :399-404
[3]  
Chen G, 1996, J CUTAN MED SURG, V1, P74
[4]   EFFECTS OF RETINOIC ACID ON IMMUNE SYSTEM - STIMULATION OF T-KILLER CELL INDUCTION [J].
DENNERT, G ;
LOTAN, R .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1978, 8 (01) :23-29
[5]   ROFERON-A (INTERFERON ALPHA-2A) COMBINED WITH TIGASON (ETRETINATE) FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMAS [J].
DRENO, B .
STEM CELLS, 1993, 11 (04) :269-275
[6]   PERIPHERAL-BLOOD MONONUCLEAR-CELLS IN PATIENTS WITH NONLEUKEMIC CUTANEOUS T-CELL LYMPHOMA - REDUCED PROLIFERATION AND PREFERENTIAL SECRETION OF A T-HELPER-2-LIKE CYTOKINE PATTERN ON STIMULATION [J].
DUMMER, R ;
KOHL, O ;
GILLESSEN, J ;
KAGI, M ;
BURG, G .
ARCHIVES OF DERMATOLOGY, 1993, 129 (04) :433-436
[7]   Combined modality therapy for cutaneous T-cell lymphoma [J].
Duvic, M ;
Lemak, NA ;
Redman, JR ;
Eifel, PJ ;
Tucker, SL ;
Cabanillas, FF ;
Kurzrock, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) :1022-1029
[8]   INTERNATIONAL-STUDIES OF THE EFFICACY OF ETRETINATE IN THE TREATMENT OF PSORIASIS [J].
EHMANN, CW ;
VOORHEES, JJ .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1982, 6 (04) :692-696
[9]   ALL-TRANS-RETINOIC ACID AND CUTANEOUS CANCERS [J].
EPSTEIN, JH .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1986, 15 (04) :772-778
[10]  
GOLDFARB RH, 1981, J IMMUNOL, V126, P2129